Home » Newsletters » BioWorld Science

BioWorld Science

April 30, 2010

View Archived Issues

Clinical data from the evaluation of Debio-025 in HCV-infected patients disclosed

Recent data support safety and potentcy of HCV NS3 protease inhibitor ACH-1625

Positive modulators of nAChRalpha7 identified at NeuroSearch

Roche claims novel gamma-secretase inhibitors

Snapshots: new reports on biomarkers related to cardiovascular disorders

Novel tachykinin NK3 receptor antagonists identified at Roche

Tibotek discloses novel CYP450 inhibitors as boosters for anti-HIV agents

Novel protein kinase inhibitors presented by Priaxon

Secreted phospholipase A2 a potential marker of traumatic brain injury

Intraprostatic botulinum toxin type A improves signs and symptoms of BPH

Padeliporfin-mediated vascular targeted phototherapy promising in prostate cancer trial

REDUCE study clarifies effects of dutasteride in prostate cancer

First quarter events at Chugai

VaxInnate presents preliminary results from phase II study of VAX-125 flu vaccine

FDA approves once-daily dosing of Kaletra for previously treated HIV patients

Prana releases position statement on PBT-2 therapeutic strategy in Alzheimer's disease

Tarceva receives E.U. approval as maintenance treatment in advanced NSCLC

Takeda submits NDA for azilsartan medoxomil to treat hypertension in the U.S.

New biotechnology company, Immunovo, secures seed funding

New company LipimetiX created to focus on lipid-lowering treatments

FDA issues complete response letter for Giazo NDA

PolyMedix initiates phase Ib/II dose-ranging PMX-60056 study

Ceregene starts new phase I/II study of CERE-120 for Parkinson's disease

Johns Hopkins and the New York Stem Cell Foundation to collaborate on stem cell research

Dendreon receives FDA approval for Provenge for castrate-resistant prostate cancer

NexMed's NexACT technology improves delivery and activity of Angstrom's A6 anticancer compound

Hana Biosciences completes pre-NDA meeting with FDA for Marqibo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...